KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Restructuring Costs (2016 - 2024)

Historic Restructuring Costs for Travere Therapeutics (TVTX) over the last 4 years, with Q4 2024 value amounting to $1.4 million.

  • Travere Therapeutics' Restructuring Costs fell 8768.65% to $1.4 million in Q4 2024 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 8871.19%. This contributed to the annual value of $2.4 million for FY2024, which is 7860.28% down from last year.
  • Per Travere Therapeutics' latest filing, its Restructuring Costs stood at $1.4 million for Q4 2024, which was down 8768.65% from $123000.0 recorded in Q3 2024.
  • Over the past 5 years, Travere Therapeutics' Restructuring Costs peaked at $11.4 million during Q4 2023, and registered a low of $123000.0 during Q3 2024.